Tactile Systems Technology, Inc
15.18-0.17 (-1.11%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · TCMD · USD
Key Stats
Market Cap
338.39MP/E (TTM)
24.48Basic EPS (TTM)
0.62Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Tactile Systems Technology, Inc. reports Q2 2025 results with revenue up 8% y/y to $78.9M, driven by 52% growth in airway clearance products, but net income down 25% to $3.2M due to higher operating expenses. YTD revenue grew 4% to $140.2M, but net income fell 88% to $0.2M amid rising costs. Cash balance was $81.5M, down from $94.4M at YE 2024, with $15.2M YTD operating cash flow. The company repurchased $30M in shares and refinanced its credit facility to $40M revolving commitment.
8-K
Q2 revenue up 7.8%
Tactile Medical reported Q2 2025 revenue of $78.9 million, up 7.8% year-over-year, driven by 52% growth in airway clearance products to $12.9 million while lymphedema sales rose 2% to $66.0 million. Gross margin improved to 75%, but net income fell to $3.2 million amid higher operating expenses from strategic investments. The company completed its $30 million share repurchase and updated 2025 guidance to $310–315 million in revenue and $33–35 million adjusted EBITDA. Momentum builds, yet profitability pressures persist.
8-K
2025 Equity Plan Approved
Tactile Systems Technology's stockholders approved the 2025 Equity Incentive Plan on May 7, 2025, authorizing 1,850,000 shares for options, RSUs, and other awards to employees, directors, and consultants, while halting grants under the 2016 plan. This refresh aligns incentives with long-term success, recycling forfeited shares to sustain equity motivation. No further awards under the old plan.
10-Q
Q1 FY2025 results
Tactile Systems held steady with $61.3 million in Q1 revenue, up 0.3% year-over-year, as airway clearance products surged 22% to $10.7 million while lymphedema dipped 3% to $50.6 million amid sales team cuts. Gross margin climbed to 74% from 71%, thanks to lower manufacturing and warranty costs, yet operating expenses rose 8% to $49.9 million, driven by higher reimbursement and admin outlays, yielding an operating loss of $4.5 million versus $3.0 million last year. Net loss widened to $3.0 million or $(0.13) per diluted share on 23.7 million shares, with the gap from operating loss tied to interest and taxes. Cash dipped to $83.6 million after $10.0 million in share repurchases, but free cash flow stayed positive at $10,000 (derived); debt holds at $25.5 million under a compliant credit facility maturing August 2026. Qui tam suits under the False Claims Act loom as a regulatory shadow.
8-K
Q1 revenue flat, guidance lowered
Tactile Medical reported Q1 2025 revenue of $61.3 million, up 0.3% year-over-year, driven by 22% growth in airway clearance products to $10.7 million, yet offset by a 3% dip in lymphedema sales to $50.6 million due to sales team adjustments. Gross margin improved to 74% from 71%, but operating expenses rose 8% on strategic investments, yielding a $3.0 million net loss and $0.3 million Adjusted EBITDA loss. The company repurchased $10.0 million in stock and expanded Nimbl for lower extremity lymphedema. It trimmed 2025 guidance to $309–$315 million revenue and $32–$34 million Adjusted EBITDA, citing temporary productivity hits. Sales optimization disrupted short-term output.
ELMD
Electromed, Inc.
24.01-0.43
EMED
Electromedical Technologies, In
0.00+0.00
HSDT
Solana Company
6.78+0.17
INSP
Inspire Medical Systems, Inc.
75.17-2.00
NMTC
NeuroOne Medical Technologies C
0.79-0.03
NXL
Nexalin Technology, Inc.
1.55+0.07
SENS
Senseonics Holdings, Inc.
7.25+0.05
TMDX
TransMedics Group, Inc.
134.32+4.61
VERO
Venus Concept Inc.
2.18+0.05
VMD
Viemed Healthcare, Inc.
6.54-0.32